Brian Lian - Feb 9, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: President & CEO, Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Stock symbol: VKTX
Transactions as of: Feb 9, 2024
Transactions value $: -$1,345,500
Form type: 4
Date filed: 2/9/2024, 08:59 PM
Previous filing: Feb 8, 2024
Next filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Sale	-$1.35M	-45K	-2.06%	$29.90	2.14M	Feb 9, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023.